Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis
Research and Practice in Thrombosis and Haemostasis · 2026-10 · 10 (7) · 106954
DOI: 10.1016/j.rpth.2026.106954 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026-10. Verfasst von Kristina Lindsley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Evidence Synthesis, IQVIA, Falls Church, Virginia, USA. Hauptthemen laut MEDLINE: Hemophilia B, Factor IX, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Background
Haemophilia B is a rare, X-linked disorder leading to deficient or dysfunctional clotting factor IX (FIX) and bleeding complications.
Objectives
The objective of this systematic review and meta-analysis was to summarise bleeding events in people with haemophilia B of any severity without inhibitors receiving prophylactic FIX replacement therapies to better understand disease burden and unmet needs.
Methods
A systematic search was conducted to identify clinical trials and observational studies reporting ABR, annualised joint bleeding rate, spontaneous bleeding events, traumatic bleeding events, and percentage of patients with zero bleeding events. Bleeding outcomes were specified as total, treated, or unspecified and analysed using the random-effects model. Subgroup meta-analyses assessed differences by age, treatment type, follow-up duration, and publication date, when feasible.
Results
The search yielded 5,684 citations; 24 clinical trials and 53 observational studies were included in the meta-analysis. Treated ABR was 2.23 (95% confidence interval [CI] 1.52, 3.27) in 13 trials; treated or unspecified ABR was 2.25 (95% CI 1.67, 3.03) in 22 trials. In 48 observational studies, treated or unspecified ABR was 2.08 (95% CI 1.62, 2.66). ABR was generally lower for patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evidence Synthesis, IQVIA, Falls Church, Virginia, USA.
- Evidence Synthesis, IQVIA, San Mateo, California, USA.
- Pfizer, New York City, New York, USA.
- Pfizer, Montreal, Quebec, Canada.
- Pfizer, Collegeville, Pennsylvania, USA.
- Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Förderung
- Pfizer Inc
Zitieren
APA
Lindsley, K., Nevo, A., Colavecchia, C., Wilcox, L. J., Patel, P., Estevez, C., Khanji, C., Uyei, J., Pipe, S. W., & Young, G. (2026). Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis, 10(7), 106954. https://doi.org/10.1016/j.rpth.2026.106954
Vancouver
Lindsley K, Nevo A, Colavecchia C, Wilcox LJ, Patel P, Estevez C, et al. Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 2026;10(7):106954. doi:10.1016/j.rpth.2026.106954
BibTeX
@article{Lindsley2026,
author = {Lindsley, Kristina and Nevo, Arianna and Colavecchia, Carmine and Wilcox, Lisa J and Patel, Priya and Estevez, Carlos and Khanji, Cynthia and Uyei, Jennifer and Pipe, Steven W and Young, Guy},
title = {Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
volume = {10},
number = {7},
pages = {106954},
doi = {10.1016/j.rpth.2026.106954}
}
EUVIMED